Elusys Therapeutics Inc., of Pine Brook, N.J., said obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severities in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.